Aquestive Therapeutics (AQST) Other financing activities (2017 - 2026)

Aquestive Therapeutics' Other financing activities history runs 9 years deep, the most recent figure standing at $1000.0 for Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $1000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 1950.0% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 1795.52% from the prior year.
• Other financing activities fell to $1000.0 in Q1 2026 per AQST's latest filing, from $1.2 million in the prior quarter.
• Across five years, Other financing activities topped out at $12.5 million in Q2 2023 and bottomed at -$12.5 million in Q3 2023.
• The 5-year median for Other financing activities is $14000.0 (2025), against an average of $401000.0.
• Across the five-year window, Other financing activities slumped 2836.7% in 2022 and surged 3275.68% in 2025, its largest moves.
• Year by year, Other financing activities stood at -$3.0 million in 2022, then jumped by 254.61% to $4.6 million in 2023, then slumped by 99.2% to $37000.0 in 2024, then jumped by 3275.68% to $1.2 million in 2025, then sank by 99.92% to $1000.0 in 2026.
• Per Business Quant, the three latest AQST Other financing activities figures stand at $1000.0 (Q1 2026), $1.2 million (Q4 2025), and $7000.0 (Q3 2025).